Success Metrics

Clinical Success Rate
75.0%

Based on 3 completed trials

Completion Rate
75%(3/4)
Active Trials
2(20%)
Results Posted
167%(5 trials)
Terminated
1(10%)

Phase Distribution

Ph phase_2
3
30%
Ph phase_3
4
40%
Ph phase_1
3
30%

Phase Distribution

3

Early Stage

3

Mid Stage

4

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
3(30.0%)
Phase 2Efficacy & side effects
3(30.0%)
Phase 3Large-scale testing
4(40.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

3 of 6 finished

Non-Completion Rate

50.0%

3 ended early

Currently Active

2

trials recruiting

Total Trials

10

all time

Status Distribution
Active(2)
Completed(3)
Terminated(3)
Other(2)

Detailed Status

Completed3
unknown2
Withdrawn2
Recruiting1
Terminated1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
2
Success Rate
75.0%
Most Advanced
Phase 3

Trials by Phase

Phase 13 (30.0%)
Phase 23 (30.0%)
Phase 34 (40.0%)

Trials by Status

recruiting110%
unknown220%
withdrawn220%
terminated110%
active_not_recruiting110%
completed330%

Recent Activity

2 active trials
Showing 5 of 10
active_not_recruitingphase_3

Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor

NCT00379340
recruitingphase_2

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia

NCT03136146
completedphase_3

Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma

NCT00567567
withdrawnphase_1

Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia

NCT03851081
unknownphase_1

PK Study on Ready-to-Use Injection (VSLI-RTU) 1 Vial & 3 Vial Formulation Marqibo® in Hematological Malignant Patients

NCT04243434
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT00379340Phase 3

Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor

Active Not Recruiting
NCT03136146Phase 2

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia

Recruiting
NCT00567567Phase 3

Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma

Completed
NCT03851081Phase 1

Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia

Withdrawn
NCT04243434Phase 1

PK Study on Ready-to-Use Injection (VSLI-RTU) 1 Vial & 3 Vial Formulation Marqibo® in Hematological Malignant Patients

Unknown
NCT02337478Phase 2

Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Terminated
NCT01055314Phase 2

Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma

Completed
NCT00025259Phase 3

Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease

Completed
NCT02861040Phase 1

Volasertib and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

Withdrawn
NCT02072785Phase 3

Phase III Study of Vincristine Sulfate Liposome For Injection In Adults With Naïve Acute Lymphoblastic Leukemia

Unknown

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10